Qelbree (Viloxazine HCl) Patent Expiration, LOE Window & CMS Spending
Qelbree (Viloxazine HCl) by Supernus: FDA Orange Book LOE 2035-04-02, 0 AB generics, $187.2M 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Supernus |
| FDA Application & Pathway | N211964 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2035-04-02 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $187.2M |
| 2024 Medicare Part D Spend | $6.8M |
| 2024 Medicaid Spend | $180.4M |
| Reported Wholesale Price Change (CA SB 17) | 11 WAC filings (max 19.1% 2-yr change) |